Abstract
AbstractLINE-1 (L1), the most abundant family of autonomous retrotransposons occupying over 17% of human DNA, is epigenetically silenced in normal tissues but frequently derepressed in cancer, suggesting that L1-encoded proteins may act as tumor-associated antigens recognized by the immune system. Here, we established an immunoassay for detecting circulating autoantibodies against L1 proteins in human blood. Using this assay in >3,000 individuals with or without cancer, we observed significantly higher IgG titers against L1-encoded ORF1p and ORF2p in patients with lung, pancreatic, ovarian, esophageal, and liver cancers compared to healthy individuals. Remarkably, elevated levels of anti-ORF1p-reactive IgG were observed in cancer patients with disease stages 1 and 2, indicating that immune response to L1 antigens can occur at early phases of carcinogenesis. We conclude that the antibody response against L1 antigens could contribute to the diagnosis and determination of immunoreactivity of tumors among cancer types that frequently escape early detection.
Publisher
Cold Spring Harbor Laboratory
Reference71 articles.
1. Autoantibodies targeting LINE-1-encoded ORF1p are associated with systemic lupus erythematosus diagnosis but not disease activity;Clin Exp Rheumatol,2022
2. The Human Long Interspersed Element-1 Retrotransposon: An Emerging Biomarker of Neoplasia
3. LINE-1 ORF2p expression is nearly imperceptible in human cancers;Mob DNA,2019
4. Somatic retrotransposition alters the genetic landscape of the human brain
5. Male Germline Control of Transposable Elements1